49 related articles for article (PubMed ID: 21152454)
1. Molecule of the month. Olaparib.
Drug News Perspect; 2010 Nov; 23(9):606. PubMed ID: 21152454
[No Abstract] [Full Text] [Related]
2. Olaparib effective in four advanced cancers.
Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
4. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
5. The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment.
McNeil EM; Ritchie AM; Melton DW
DNA Repair (Amst); 2013 Nov; 12(11):1000-6. PubMed ID: 24070777
[TBL] [Abstract][Full Text] [Related]
6. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
Gartner EM; Burger AM; Lorusso PM
Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
[TBL] [Abstract][Full Text] [Related]
7. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Sahin I; Ararat E; Altundag K
J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
[No Abstract] [Full Text] [Related]
8. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
[TBL] [Abstract][Full Text] [Related]
9. Combining carefully selected drug, patient genetics may lead to total tumor death.
Tuma RS
J Natl Cancer Inst; 2007 Oct; 99(20):1505-6, 1509. PubMed ID: 17925530
[No Abstract] [Full Text] [Related]
10. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality--a new direction in cancer-drug development.
Iglehart JD; Silver DP
N Engl J Med; 2009 Jul; 361(2):189-91. PubMed ID: 19553640
[No Abstract] [Full Text] [Related]
12. Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
Falchi F; Giacomini E; Masini T; Boutard N; Di Ianni L; Manerba M; Farabegoli F; Rossini L; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Roberti M; Pellicciari R; Cavalli A
ACS Chem Biol; 2017 Oct; 12(10):2491-2497. PubMed ID: 28841282
[TBL] [Abstract][Full Text] [Related]
13. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
Chen Y; Zhang L; Hao Q
Arch Gynecol Obstet; 2013 Aug; 288(2):367-74. PubMed ID: 23619942
[TBL] [Abstract][Full Text] [Related]
14. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
Plummer R
Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():121-5. PubMed ID: 24145016
[TBL] [Abstract][Full Text] [Related]
17. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
18. The DNA-damage response: new molecular insights and new approaches to cancer therapy.
Jackson SP
Biochem Soc Trans; 2009 Jun; 37(Pt 3):483-94. PubMed ID: 19442242
[TBL] [Abstract][Full Text] [Related]
19. Getting personal with prostate cancer: DNA-repair defects and olaparib in metastatic prostate cancer.
Raison N; Elhage O; Dasgupta P
BJU Int; 2017 Jan; 119(1):8-9. PubMed ID: 27154575
[No Abstract] [Full Text] [Related]
20. [Not Available].
Li DQ; Kumar R
Hepatology; 2013 Mar; 57(3):1287-8. PubMed ID: 22815144
[No Abstract] [Full Text] [Related]
[Next] [New Search]